Speedel launches independent Phase III trial

Switzerland's Speedel has initiated a Phase III trial of its experimental SPP 301 for diabetic kidney disease. Company officials touted the move as a milestone of "major strategic importance," noting that it's the first Phase III trial that Speedel has launched alone. SPP 100 is in Phase III -- with Novartis as a partner -- for hypertension. Speedel believes that both drugs have blockbuster potential.

- read this story from AFX for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.